Is Takeda Pharmaceutical Company Limited (TAK) Stock Positioned for Growth After Strong LATITUDE Atlas Study Data?

We recently compiled a list of the 12 Best Low-Priced Pharma Stocks to Buy Right Now. Takeda Pharmaceutical Company Limited (NYSE:TAK) is one of the best low-priced pharma stocks on this list.

TheFly reported on June 23 that TAK announced positive topline findings from its Phase 3 LATITUDE Atlas study evaluating zasocitinib, an investigational oral TYK2 inhibitor, in adults with moderate-to-severe plaque psoriasis. The trial demonstrated that zasocitinib outperformed deucravacitinib on the primary endpoint, achieving superior PASI 100 response rates at Week 16. The therapy also met all major secondary endpoints, including PASI 90 and Static Physician’s Global Assessment 0 responses. Zasocitinib maintained a favorable safety and tolerability profile throughout the study, with no new safety concerns identified. The global trial enrolled 606 participants across eight countries, including 73 patients treated at 18 Canadian sites.

Separately, earlier on June 9, Takeda Pharmaceutical Company Limited (NYSE:TAK) announced that the U.S. Food and Drug Administration had accepted its supplemental Biologics License Application for intravenous ENTYVIO for pediatric patients aged 2 years and older with moderately to severely active ulcerative colitis and Crohn’s disease. The application is now under FDA review, with a Prescription Drug User Fee Act target action date expected in the first quarter of 2027. If approved, ENTYVIO IV could become the only gut-focused therapy option available for this pediatric population. The milestone highlights Takeda’s continued efforts to expand treatment options and address unmet needs for children and adolescents living with inflammatory bowel diseases.

Takeda Pharmaceutical Company Limited (NYSE:TAK) is a global biopharmaceutical company and one of Asia’s largest pharmaceutical firms, focused on developing innovative medicines across multiple therapeutic areas.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.